Tirzepatide Testing
Dual GIP/GLP-1 receptor agonist; the molecule behind Mounjaro and Zepbound. Long lipidated peptide.
Mechanism of action
Tirzepatide is a 39-residue dual GIP/GLP-1 receptor agonist with two Aib substitutions (positions 2 and 13) and a C20 fatty-diacid side chain on Lys20 via a γ-Glu spacer. Dual incretin activity drives stronger weight loss and glycemic effects than GLP-1 monotherapy in head-to-head studies (SURMOUNT-5).
Sequence & structure
C-terminal amidation, two Aib residues, and C20 diacid lipidation place this molecule at the edge of solid-phase peptide synthesis difficulty. Lot-to-lot variability in compounded material is substantially higher than for semaglutide.
Research areas
- ●Type 2 diabetes (Mounjaro)
- ●Obesity (Zepbound)
- ●Obstructive sleep apnea (FDA-approved 2024)
- ●MASH research
- ●Heart failure with preserved EF (SUMMIT trial)
Dosing in the literature
Titrated 2.5 mg → 15 mg weekly. Compounded vials typically sold at 10–40 mg/vial. Apollo data on compounded tirzepatide lots: median assay ~87% of label, with a meaningful fraction under 70%.
For research/informational purposes only — not medical advice.
What we test on Tirzepatide
Standard panel: RP-HPLC purity on a wide-pore C8 with extended gradient; intact-mass and top-down LC-MS/MS confirmation on Orbitrap. We report Aib position confirmation (b/y ion mapping), free diacid %, oxidation %, and concentration vs. label by external standard.
- ✓RP-HPLC purity (UV 214 nm)
- ✓LC-MS/MS identity (Orbitrap)
- ✓Counter-ion / residual TFA
- ✓Water content (KF)
- ✓Endotoxin (LAL, USP <85>)
Common impurities & failure modes
- Des-Aib2 / Des-Aib13
Loss of either Aib eliminates DPP-4 protection at that site. High-res MS required — mass shift is only 71 Da and both fragments co-elute in standard methods.
- Free C20 diacid
Late-eluting; quantified by extending the gradient. Common when acylation chemistry runs incompletely.
- Methionine oxidation (Met14)
+16 Da shift; minor activity loss but flags storage issues.
- Cross-contamination with semaglutide
Compounding facilities running both products frequently show low-level cross-over; intact-mass LC-MS easily distinguishes the ~700 Da difference.
- C-terminal free acid (failed amidation)
−1 Da shift; reduces receptor affinity significantly.
Storage & stability
2–8 °C lyophilized; reconstituted stable ~21 days refrigerated.
Regulatory status
FDA-approved (Mounjaro 2022, Zepbound 2023).
Frequently asked questions
Why does compounded tirzepatide vary so much?+
The synthesis is hard. Dual lipidation and two Aib residues mean any compounding facility without a peptide-chemistry specialist will see lower yields and more side-products.
Can you distinguish tirzepatide from retatrutide?+
Yes — they differ by ~640 Da intact mass and have completely different MS/MS fingerprints.